NFE2L2 and hepatocellular carcinoma: Current studies suggest that the negative regulator of ferroptosis, metallothionein-1g (MT-1G) (Sun et al., 2016a), the activation of nuclear factor erythroid 2-related factor 2 (NRF2) (Sun et al., 2016b), and the transcription factor yes-associated protein/transcriptional coactivator with PDZ-binding motif (YAP/TAZ) all inhibit ferroptosis (Gao et al., 2021), which may be the main mechanism of drug resistance in the treatment of HCC by sorafenib (Nie et al., 2018).